logo
High Seas Treaty gains momentum as 18 new countries pledge support

High Seas Treaty gains momentum as 18 new countries pledge support

Washington Post6 hours ago

NICE, France — Eighteen countries ratified the High Seas Treaty on Monday, bringing the total to 49 — just 11 short of the 60 needed for the ocean agreement to enter into force. The surge in support, occurring during the U.N. Ocean Conference in Nice, France, adds momentum to what could become a historic shift in how the world governs the open ocean.
Here's what the treaty is, why it matters and what happens next.
Formally known as the Agreement on Biodiversity Beyond National Jurisdiction, the High Seas Treaty is the first legally binding agreement focused on protecting marine biodiversity in international waters. These waters, which are beyond the jurisdiction of any single country, make up nearly two-thirds of the ocean and almost half the surface of the planet.
Until now, there has been no comprehensive legal framework to create marine protected areas or enforce conservation on the high seas.
Despite their remoteness, the high seas are under growing pressure from overfishing, climate change and the threat of deep-sea mining . Environmental advocates warn that without proper protections, marine ecosystems in international waters face irreversible harm.
'Until now, it has been the wild west on the high seas,' said Megan Randles, global political lead for oceans at Greenpeace. 'Now we have a chance to properly put protections in place.'
The treaty is also essential to achieving the global '30x30' target — an international pledge to protect 30% of the planet's land and sea by 2030.
The treaty creates a legal process for countries to establish marine protected areas in the high seas, including rules for destructive activities like deep-sea mining and geo-engineering. It also establishes a framework for technology-sharing, funding mechanisms and scientific collaboration among countries.
Crucially, decisions under the treaty will be made multilaterally through conferences of parties (COPs) rather than by individual countries acting alone.
Once 60 countries ratify the treaty, a 120-day countdown begins before it officially enters into force. That would unlock the ability to begin designating protected areas in the high seas and put oversight mechanisms into motion.
As of Monday evening, 49 countries and the EU had ratified, meaning 11 more are needed to trigger that countdown.
The first Conference of the Parties (COP1) must take place within one year of the treaty's entry into force. That meeting will lay the groundwork for implementation, including decisions on governance, financing and the creation of key bodies to evaluate marine protection proposals.
Environmental groups are pushing to surpass the required 60 ratifications, and to do so quickly – the more countries that ratify, the stronger and more representative the treaty's implementation will be. There's also a deadline: only countries that ratify by COP1 will be eligible to vote on critical decisions that determine how the treaty will operate.
'To reach 60 ratifications would be an absolutely enormous achievement, but for the treaty to be as effective as possible, we need countries from all over the world to engage in its implementation,' said Rebecca Hubbard, director of the High Seas Alliance. 'So the next step will be to go from 60 to global.'
The surge in support on Monday has raised hopes that 2025 could mark a turning point for high seas protection.
'We're on the brink of making high seas history,' Hubbard said.
___
Follow Annika Hammerschlag on Instagram @ahammergram
___
The Associated Press receives support from the Walton Family Foundation for coverage of water and environmental policy. The AP is solely responsible for all content. For all of AP's environmental coverage, visit https://apnews.com/hub/climate-and-environment

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Biovica Secures Three New Work Orders in Pharma Services of 2,5 MSEK in Value
Biovica Secures Three New Work Orders in Pharma Services of 2,5 MSEK in Value

Yahoo

timean hour ago

  • Yahoo

Biovica Secures Three New Work Orders in Pharma Services of 2,5 MSEK in Value

UPPSALA, SE / / June 10, 2025 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, a leader in blood-based cancer monitoring, has signed three new work orders within its Pharma Services business, with a combined value of approximately SEK 2.5 million. The agreements are for TKa testing services with existing customers. Two of the three work orders were placed by the Tier-1 (revenues >10 BUSD) U.S. pharmaceutical company which recently entered into a broader service agreement with Biovica, including a record-breaking SEK 4 million work order. These latest orders will support the development of next-generation CDK4/6 inhibitors. The orders are a combination of retrospective analysis, that will be performed in the coming months, and prospective analysis that will be performed over ~2 years. "I'm pleased to see that our Pharma customers recognize the value of DiviTum® TKa and are returning for continued use. The reliable and meaningful data it provides continues to drive demand from leading pharmaceutical companies, who use it in the development of new cancer therapies that will benefit patients.," said Anders Rylander, CEO of Biovica. Contact Anders Rylander, CEOPhone: +46 76 666 16 47E-mail: Anders Morén, CFOPhone: +46 73 125 92 46E-mail: Biovica - Treatment decisions with greater confidence Biovica develops and commercializes blood-based biomarker assays that help oncologists monitor cancer progression. Biovica's assay, DiviTum® TKa, measures cell proliferation by detecting the TKa biomarker in the bloodstream. The assay has demonstrated its ability to provide insight to therapy effectiveness in several clinical trials. The first application for the DiviTum® TKa test is treatment monitoring of patients with metastatic breast cancer. Biovica's vision is: "Improved care for cancer patients." Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum® TKa has received FDA 510(k) clearance in the US and is CE-marked in the EU. Biovica's shares are traded on the Nasdaq First North Premier Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser. For more information, please visit: Attachments Biovica secures three new work orders in Pharma Services of 2,5 MSEK in value SOURCE: Biovica International View the original press release on ACCESS Newswire

FG001 clinical data in High-Grade Glioma is now published in Neurosurgery
FG001 clinical data in High-Grade Glioma is now published in Neurosurgery

Yahoo

timean hour ago

  • Yahoo

FG001 clinical data in High-Grade Glioma is now published in Neurosurgery

KØBENHAVN, DK / / June 10, 2025 / FluoGuide A/S (STO:FLUO) - Copenhagen, Denmark - FluoGuide A/S ("FluoGuide" or the "Company"), a clinical-stage biotech company focused on precision cancer surgery, is pleased to announce its compelling phase I clinical data with FG001 has been published in Neurosurgery. The data is the first-in-human result of its proprietary near-infrared (NIR) optical imaging agent, FG001, in patients with malignant glioma undergoing surgery. The article, published in the prestigious journal Neurosurgery, which targets neurosurgeons, is entitled "Novel uPAR-targeting optical imaging agent ICG-Glu-Glu-AE105 (FG001) for visualization of malignant glioma during surgery: First-in-human study in 35 brain cancer patients" and identified with doi:10 1227/neu.0000000000003542, available here: link. "We are very pleased with the publication of the results from this first-in-human study that shows FG001 not only enables safe and targeted tumor identification including in the transition zone, being the tissue between the cancer and normal tissue which constitutesthe biggest challenge for the surgeon treating high-grade glioma - where the agent continued to produce visible fluorescence." said Morten Albrechtsen, CEO of FluoGuide; "FG001 has the potential to redefine how surgeons approach brain tumor resection" Next clinical step and regulatory pathFollowing the successful completion of this phase I study, FluoGuide is obtaining FDA regulatory advice prior to initiate the U.S. clinical trial supporting approval of FG001 guiding surgery of patients with High Grade Glioma. FluoGuide anticipates feedback from ongoing regulatory interactions over the summer. "I am pleased to see the first result of FG001 in patients with malignant glioma published" says Jane Skjøth-Rasmussen, MD, PhD, Chief Physician in the Department of Neurosurgery at Rigshospitalet, Copenhagen, Denmark and Principal Investigator of the trial and the author of the publication, and continues: "The data demonstrates FG001 to be well tolerated and shows a promise for guiding surgery of malignant glioma." In an editorial comment published together with the article Professor Pierre A. Robe, Chair of Neurosurgical Oncology at the University Medical Center (UMC) concludes: "Altogether, the results reported here are a welcome and exciting addition to the brain tumor neurosurgical community." Please refer to the published article for the full commentary. Glioblastoma is among the most aggressive and lethal forms of brain cancer, with a crucial need for tools that enable maximal tumor resection while preserving healthy brain tissue. FG001 lights up cancer, enabling surgeons to perform more precise surgeries. It is an novel imaging agent that targets the urokinase-type plasminogen activator receptor (uPAR), a protein highly expressed in tumor tissue but largely absent from normal brain cells. Key results from the phase I studyThe result is from the first clinical trial with FG001 in patients with High Grade Glioma and is an open-label, single-center phase I trial involving 35 patients, and FG001 was administered intravenously prior to brain surgery. A dose of 36 mg administered 12-19 hours before surgery provided optimal tumor visualization. The tumor-to-background fluorescence ratio (TBR) was relevant for all image system tested (>1.5) and up to 2.7 (TBR mean) and 3.6 (TBR max). Notably, FG001 achieved a sensitivity of 79% and a specificity of 100% in identifying malignant tissue confirmed by histopathology. Compared with the imaging agent 5-ALA, FG001 was observed to provide clearer delineation in deeper tissue layers due to its NIR fluorescence properties, with no observed false positives. FG001's safety profile was equally promising, with only few (4) mild drug-related adverse events linked to the drug. It was observed that unlike 5-ALA, no FG001-related nausea or vomiting was reported in patients receiving evening doses, underscoring FG001s favorable tolerability. High precision in the transition zoneThe transition zone, being the tissue between the tumor and the normal tissue, is of special attention to neurosurgeons as it is where they must make the difficult decisions between removing tissue that may be cancer and risking disabling patients by removing more brain tissue than necessary. FG001 worked well in the transition zone where all 7 samples were correctly classified by FG001 whereas 5-ALA had 2 false negative. When the efficacy was calculated for transition zone only, then specificity, sensitivity, positive predictive value (PPV), and negative predictive value (NPV) were all 100% for FG001, whereas the numbers were 100%, 60%, 100%, and 50% for 5-ALA, respectively. For further information, please contact:Morten Albrechtsen, CEOFluoGuide A/SPhone: +45 24 25 62 66E-mail: ma@ Certified Adviser:Svensk Kapitalmarknadsgransking ABWebsite: About FluoGuideFluoGuide is a biotech company specializing in precision cancer surgery improving the outcome for cancer patients. The Company's lead product, FG001, a novel optical imaging agent that light up cancerous tissue to improve surgical precision in patients undergoing surgery. FluoGuide's products are expected to have a dual benefit - reducing both the frequency of local recurrence after surgery and reducing surgical complications. The improved precision will potentially increase the patients' chance of achieving a complete cure and lower healthcare costs. FG001 binds to the urokinase plasminogen activator receptor (uPAR) being extensively expressed by solid cancer. The photosensitizer therapy potential of FG001 could add a direct treatment effect of FG001 to further benefit for patients with cancer undergoing surgery. The Company has published strong results from phase II trials demonstrating the efficacy of FG001 in patients undergoing surgery to remove aggressive brain (high-grade glioma), head & neck (oral squamous cell carcinoma) and lung cancers (non-small cell lung cancer). FG001 has also been demonstrated very well tolerated across all patients. Based on this strong foundation, FluoGuide advances the development toward approval in aggressive brain cancer and head & neck cancer. FluoGuide is listed on Nasdaq First North Growth Market, Stockholm under the ticker "FLUO". Read more about FluoGuide and upcoming events on AttachmentsFG001 clinical data in High-Grade Glioma is now published in Neurosurgery SOURCE: FluoGuide A/S View the original press release on ACCESS Newswire

Artificial Blood: Sci-Fi Breakthrough or False Hope?
Artificial Blood: Sci-Fi Breakthrough or False Hope?

Medscape

time2 hours ago

  • Medscape

Artificial Blood: Sci-Fi Breakthrough or False Hope?

Japanese researchers have developed artificial blood, marking a significant step in this long-standing scientific pursuit. However, large-scale production remains a challenge. In France, the national blood service Établissement français du sang regularly raises alarms over critically low blood supplies, with daily donations falling short of the 10,000 units needed to meet transfusion demands. This challenge is further complicated by ABO/Rh compatibility issues, prompting targeted appeals for rare blood-type donors. This shortage is not unique to France. It is a global concern, often even more severe elsewhere, driving continued efforts to create viable artificial alternatives. Vesicle Trials Researchers at Nara University in Nara, Japan have created 'hemoglobin vesicles' (HbVs): Haemoglobin encapsulated within a lipid shell that mimics red blood cells. In a 2022 trial, investigators injected 100 mL of HbVs into 12 healthy volunteers, with no serious adverse events reported. The team plans to administer up to 400 mL to a larger cohort. If safety is confirmed, future studies will assess haemodynamic and respiratory effectiveness. Investigators hope to achieve industrial production and clinical use by 2030. Storage Benefits Artificial blood offers two key advantages over donor blood. First, it can be stored at room temperature for up to 2 years or up to 5 years if frozen, whereas donated blood expires after 6 weeks. Second, HbVs lack ABO and Rh antigens, making them theoretically compatible with all recipients. Notably, the solution turned purple. Failed Attempts The quest for artificial blood holds great promise, as tens of thousands die annually from blood shortages, particularly in low-income countries. However, previous efforts have been repeatedly stalled. In 2011, Luc Douay, MD, PhD, senior study author and Professor of Haematology at Université Pierre et Marie Curie in Paris, France, performed France's first transfusion using stem cell-derived red cells. In Japan, military physicians transfused experimental blood into rabbits in 2019 and reported encouraging results from stem cell-derived erythrocyte injections in the United Kingdom in 2022. 'All attempts have failed so far,' Douay said in 2017. While the latest Japanese trials offer renewed hope, experts emphasise the need to expand natural blood donation programs.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store